Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Effective Targeting of TAG72+ Peritoneal Ovarian Tumors via Regional Delivery of CAR-Engineered T Cells.

Murad JP, Kozlowska AK, Lee HJ, Ramamurthy M, Chang WC, Yazaki P, Colcher D, Shively J, Cristea M, Forman SJ, Priceman SJ.

Front Immunol. 2018 Nov 19;9:2268. doi: 10.3389/fimmu.2018.02268. eCollection 2018.

2.

Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma.

Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S.

Cancer Immunol Res. 2019 Jan;7(1):100-112. doi: 10.1158/2326-6066.CIR-18-0307. Epub 2018 Nov 5.

PMID:
30396908
3.

Manufacturing development and clinical production of NKG2D chimeric antigen receptor-expressing T cells for autologous adoptive cell therapy.

Murad JM, Baumeister SH, Werner L, Daley H, Trébéden-Negre H, Reder J, Sentman CL, Gilham D, Lehmann F, Snykers S, Sentman ML, Wade T, Schmucker A, Fanger MW, Dranoff G, Ritz J, Nikiforow S.

Cytotherapy. 2018 Jul;20(7):952-963. doi: 10.1016/j.jcyt.2018.05.001. Epub 2018 Jun 29.

PMID:
30180944
4.

Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies.

Murad JM, Graber DJ, Sentman CL.

Best Pract Res Clin Haematol. 2018 Jun;31(2):176-183. doi: 10.1016/j.beha.2018.03.003. Epub 2018 Mar 27. Review.

PMID:
29909918
5.

Co-stimulatory signaling determines tumor antigen sensitivity and persistence of CAR T cells targeting PSCA+ metastatic prostate cancer.

Priceman SJ, Gerdts EA, Tilakawardane D, Kennewick KT, Murad JP, Park AK, Jeang B, Yamaguchi Y, Yang X, Urak R, Weng L, Chang WC, Wright S, Pal S, Reiter RE, Wu AM, Brown CE, Forman SJ.

Oncoimmunology. 2017 Oct 16;7(2):e1380764. doi: 10.1080/2162402X.2017.1380764. eCollection 2018.

6.

Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2+ Breast Cancer Metastasis to the Brain.

Priceman SJ, Tilakawardane D, Jeang B, Aguilar B, Murad JP, Park AK, Chang WC, Ostberg JR, Neman J, Jandial R, Portnow J, Forman SJ, Brown CE.

Clin Cancer Res. 2018 Jan 1;24(1):95-105. doi: 10.1158/1078-0432.CCR-17-2041. Epub 2017 Oct 23.

7.

Perinatal Malnutrition Leads to Sexually Dimorphic Behavioral Responses with Associated Epigenetic Changes in the Mouse Brain.

Nätt D, Barchiesi R, Murad J, Feng J, Nestler EJ, Champagne FA, Thorsell A.

Sci Rep. 2017 Sep 11;7(1):11082. doi: 10.1038/s41598-017-10803-2.

8.

Human brain metastatic stroma attracts breast cancer cells via chemokines CXCL16 and CXCL12.

Chung B, Esmaeili AA, Gopalakrishna-Pillai S, Murad JP, Andersen ES, Kumar Reddy N, Srinivasan G, Armstrong B, Chu C, Kim Y, Tong T, Waisman J, Yim JH, Badie B, Lee PP.

NPJ Breast Cancer. 2017 Mar 2;3:6. doi: 10.1038/s41523-017-0008-8. eCollection 2017.

9.

Exploiting natural killer group 2D receptors for CAR T-cell therapy.

Demoulin B, Cook WJ, Murad J, Graber DJ, Sentman ML, Lonez C, Gilham DE, Sentman CL, Agaugue S.

Future Oncol. 2017 Aug;13(18):1593-1605. doi: 10.2217/fon-2017-0102. Epub 2017 Jun 14. Review.

10.

Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.

Sentman ML, Murad JM, Cook WJ, Wu MR, Reder J, Baumeister SH, Dranoff G, Fanger MW, Sentman CL.

J Immunol. 2016 Dec 15;197(12):4674-4685. Epub 2016 Nov 14.

11.

Antigen-specific inhibition of high-avidity T cell target lysis by low-avidity T cells via trogocytosis.

Chung B, Stuge TB, Murad JP, Beilhack G, Andersen E, Armstrong BD, Weber JS, Lee PP.

Cell Rep. 2014 Aug 7;8(3):871-882. doi: 10.1016/j.celrep.2014.06.052. Epub 2014 Jul 31.

12.

Current and experimental antibody-based therapeutics: insights, breakthroughs, setbacks and future directions.

Murad JP, Lin OA, Espinosa EV, Khasawneh FT.

Curr Mol Med. 2013 Jan;13(1):165-78. Review.

PMID:
22834842
13.

A novel antibody targeting the ligand binding domain of the thromboxane A₂ receptor exhibits antithrombotic properties in vivo.

Murad JP, Espinosa EV, Ting HJ, McClure D, Khasawneh FT.

Biochem Biophys Res Commun. 2012 May 11;421(3):456-61. doi: 10.1016/j.bbrc.2012.04.011. Epub 2012 Apr 7.

PMID:
22503974
14.

Mouse transient receptor potential channel 6: role in hemostasis and thrombogenesis.

Paez Espinosa EV, Murad JP, Ting HJ, Khasawneh FT.

Biochem Biophys Res Commun. 2012 Jan 13;417(2):853-6. doi: 10.1016/j.bbrc.2011.12.058. Epub 2011 Dec 20.

PMID:
22206677
15.

Aspirin: pharmacology and clinical applications.

Paez Espinosa EV, Murad JP, Khasawneh FT.

Thrombosis. 2012;2012:173124. doi: 10.1155/2012/173124. Epub 2011 Nov 17.

16.

Characterization of the in vivo antiplatelet activity of the antihypertensive agent losartan.

Murad JP, Espinosa EV, Ting HJ, Khasawneh FT.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):308-14. doi: 10.1177/1074248411425491. Epub 2011 Nov 28.

PMID:
22123197
17.

Thromboxane A2 receptor: biology and function of a peculiar receptor that remains resistant for therapeutic targeting.

Ting HJ, Murad JP, Espinosa EV, Khasawneh FT.

J Cardiovasc Pharmacol Ther. 2012 Sep;17(3):248-59. doi: 10.1177/1074248411424145. Epub 2011 Nov 7. Review.

PMID:
22064668
18.

The C-terminal segment of the second extracellular loop of the thromboxane A2 receptor plays an important role in platelet aggregation.

Murad JP, Espinosa EV, Ting HJ, Khasawneh FT.

Biochem Pharmacol. 2012 Jan 1;83(1):88-96. doi: 10.1016/j.bcp.2011.10.002. Epub 2011 Oct 8.

PMID:
22008592
19.

Inhibitor of DNA binding 4 (ID4) regulation of adipocyte differentiation and adipose tissue formation in mice.

Murad JM, Place CS, Ran C, Hekmatyar SK, Watson NP, Kauppinen RA, Israel MA.

J Biol Chem. 2010 Jul 30;285(31):24164-73. doi: 10.1074/jbc.M110.128744. Epub 2010 May 11.

20.

ID2 (inhibitor of DNA binding 2) is a rhythmically expressed transcriptional repressor required for circadian clock output in mouse liver.

Hou TY, Ward SM, Murad JM, Watson NP, Israel MA, Duffield GE.

J Biol Chem. 2009 Nov 13;284(46):31735-45. doi: 10.1074/jbc.M109.013961. Epub 2009 Sep 9.

21.

Evaluation of molecular markers in hepatic metastasis of colorectal adenocarcinoma.

Murad JC, Ribeiro U Jr, Safatle-Ribeiro AV, Parra E, Rawet V, Corbett CE, Ferreira VA, Pugliese V, Saad WA, Habr-Gama A, Gama-Rodrigues J.

Hepatogastroenterology. 2007 Jun;54(76):1029-33.

PMID:
17629032
22.

PKR activation by a non-coding RNA expressed in lymphocytes of mice bearing B16 melanoma.

Murad JM, de Souza LR, De Lucca FL.

Blood Cells Mol Dis. 2006 Sep-Oct;37(2):128-33. Epub 2006 Jul 20.

PMID:
16857398
23.

Activation of the RNA-dependent protein kinase (PKR) of lymphocytes by regulatory RNAs: implications for immunomodulation in HIV infection.

Watanabe MA, de Souza LR, Murad JM, De Lucca FL.

Curr HIV Res. 2005 Oct;3(4):329-37. Review.

PMID:
16250880
24.

A point mutation in the RNA-binding domain I results in decrease of PKR activation in acute lymphoblastic leukemia.

Murad JM, Tone LG, de Souza LR, De Lucca FL.

Blood Cells Mol Dis. 2005 Jan-Feb;34(1):1-5.

PMID:
15607693
25.

Regulatory RNA induces the production of IFN-gamma, but not IL-4 in human lymphocytes: role of RNA-dependent protein kinase (PKR) and NF-kappaB.

De Lucca FL, Sales VS, Souza LR, Murad JM, Watanabe MA.

Mol Cell Biochem. 2003 May;247(1-2):211-7.

PMID:
12841650
26.

Antitumor activity induced by regulatory RNA: possible role of RNA-dependent protein kinase and nuclear factor-kappaB.

Watanabe MA, Rodrigues Souza L, Murad JM, De Lucca FL.

Eur J Pharmacol. 2003 Apr 4;465(3):205-10.

PMID:
12681431
27.

Effects of propolis from Brazil and Bulgaria on fungicidal activity of macrophages against Paracoccidioides brasiliensis.

Murad JM, Calvi SA, Soares AM, Bankova V, Sforcin JM.

J Ethnopharmacol. 2002 Mar;79(3):331-4.

PMID:
11849837
28.

Stab wounds associated with terrorist activities in Israel.

El-Murad J.

JAMA. 1997 Jan 1;277(1):21; author reply 22. No abstract available.

PMID:
8980202
29.

Guide to safety in the workplace. Part II: occupational exposure to bloodborne pathogens.

Little LM, Murad JL.

Clin Lab Sci. 1993 May-Jun;6(3):161-3. No abstract available.

PMID:
10146216
30.

Drug abuse among students in the State of Minas Gerais, Brazil.

Murad JE.

Bull Narc. 1979 Jan-Mar;31(1):49-58. No abstract available.

PMID:
260894
31.

Psychopharmacological properties of the viminol-p-hydroxybenzoate.

Neto JM, Murad JE, Monteiro SS.

Rev Bras Pesqui Med Biol. 1977 Dec;10(6):361-8.

PMID:
609773
32.

Diplogasterid and rhabditid nematodes in wastewater treatment plant and factors related to their dispersal.

Murad JL, Bazer GT.

J Water Pollut Control Fed. 1970 Jan;42(1):106-14. No abstract available.

PMID:
5412145
33.

Pharmacological properties of a Brazilian plant, the Dimorphandra mollis Benth.

Murad JE, Lacombe O, Santana M, Fortini LG.

Hospital (Rio J). 1969 Apr;75(4):1357-65. No abstract available.

PMID:
5306427
34.

[Teratogenic molecules].

Murad JE.

Hospital (Rio J). 1967 Jul;72(1):277-86. Review. Portuguese. No abstract available.

PMID:
4877107
35.

Association between biochemical and behavioral actions of tricyclic antidepressants.

Murad JE, Shore PA.

Int J Neuropharmacol. 1966 Jul;5(4):299-304. No abstract available.

PMID:
5965643
36.

[Stimulating action of anorexigenics on mice--the actograph test].

Murad JE, Lenza DP, Salgado FA.

Arq Cent Estud Fac Odontol UFMG (Belo Horiz). 1965 Jul-Dec;2(2):135-40. Portuguese. No abstract available.

PMID:
5218412
37.

[AMELIA AND MICROMELIA INDUCED BY THALIDOMIDE IN THE MOUSE FETUS].

MURAD JE, ALVARENGA RJ.

Therapie. 1964 Sep-Oct;19:1405-9. French. No abstract available.

PMID:
14227800
38.

[Pharmacological study of trimethoxybenzoic acid derivatives].

PIMENTA A, MURAD JE, BAIA GV, LENZA DP.

Therapie. 1962 Nov-Dec;17:1189-1200. French. No abstract available.

PMID:
13943628
40.
41.

[Neuroplegic treatment of poliomyelitis].

Matera FC, Alvarez AR, Badia I, Bugarini H, Landoni JF, Mesz B, Mendilharzu F, Mandilharzu JL, Murad J, Quintana H.

Anesth Analg (Paris). 1957 Mar-Apr;14(2):254-9. French. No abstract available.

PMID:
15445016
42.

[Hibernotherapy in poliomyelitis].

MATERA FC, BADIA IB, LANDONI FERNANDEZ J, MENDILAHARZU F, MURAD J, ALVAREZ AR, BUGARINI H, MESZ B, MENDILAHARZU J, QUINTANA H.

Dia Med. 1956 May 14;28(31):784-6. Italian, Spanish. No abstract available.

PMID:
13330577

Supplemental Content

Support Center